Mitogen-activated protein kinase kinase 4 (MAPKK4) (MAPKK4)

Mitogen-activated protein kinase kinase 4 (MAPKK4), also known as MKK4 or MAP2K4, is a pivotal dual-specificity protein kinase that occupies a central position in the mitogen-activated protein kinase (MAPK) signaling architecture. It is primarily responsible for the dual phosphorylation and subsequent activation of c-Jun N-terminal kinases (JNK) and p38 MAPKs in response to a variety of environmental stressors, pro-inflammatory cytokines, and growth factors (UniProt P45985). Through these pathways, MAPKK4 regulates diverse cellular processes including apoptosis, cell cycle progression, and differentiation (PubMed: 25103309). In oncology, MAPKK4 is recognized for its complex, context-dependent role; it functions as a metastasis suppressor in cancers such as prostate and ovarian cancer, yet it may promote tumor growth or survival in other malignancies like pancreatic cancer (PubMed: 15894603). Beyond its role in cancer, MAPKK4 is implicated in the pathogenesis of inflammatory and neurodegenerative conditions, making it a target of interest for therapeutic modulation. Small molecule inhibitors, including the isoflavone genistein and various synthetic research compounds, have been explored for their ability to block MAPKK4-mediated signaling and inhibit cancer cell migration (PubMed: 21163910). However, the development of MAPKK4-targeted therapies is challenged by its dual biological nature, necessitating a deep understanding of the specific disease context to avoid adverse outcomes.

Other names

MAP2K4MKK4JNKK1SEK1SERK1SKK1Dual specificity mitogen-activated protein kinase kinase 4

Small molecule inhibition of the kinase domain, preventing the phosphorylation of downstream substrates JNK and p38 MAPK.